Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

Elite now has a complete "Hammer Lock" on the 2-bead pharmacologicals ADT Opioid family of ELI216s for the next 17 to 20 years for various opioid agonists and various opioid antagonists. Elite's two Patents and one Patent Application are:

Patent 8,182,836
Patent 8,425,933
Patent Application 13/863,764 Patent pending.


Patent Application 12/075,816 is now officially abandoned and replaced by Patent Application 13/863,764

Elite's first agonist/antagonist ELI216 to be submitted for 505b2 approval is expected to be oxycodone/naltrexone as ELI216-OXY/NAL. The FDA submittal is expected by mid-2014 or sooner following 38 persons studies starting Nov/Dec 2013. Based on latest info in Patent Application 13/863,764, the second agonist/antagonist ELI216 submitted for 505b2 approval is expected to be morphine/naltrexone as ELI216-MOR/NAL. Its FDA submittal is expected to parallel ELI216-OXY/NAL or very shortly thereafter. More agonist ELI216s submittals are expected to follow such as hydrocodone, hydromorphone, codeine etc.